BR112017022321A2 - clonidina e/ou derivados de clonidina para uso na prevenção e/ou no tratamento de efeitos colaterais adversos da quimioterapia - Google Patents

clonidina e/ou derivados de clonidina para uso na prevenção e/ou no tratamento de efeitos colaterais adversos da quimioterapia

Info

Publication number
BR112017022321A2
BR112017022321A2 BR112017022321-0A BR112017022321A BR112017022321A2 BR 112017022321 A2 BR112017022321 A2 BR 112017022321A2 BR 112017022321 A BR112017022321 A BR 112017022321A BR 112017022321 A2 BR112017022321 A2 BR 112017022321A2
Authority
BR
Brazil
Prior art keywords
clonidine
treatment
side effects
prevention
chemotherapy
Prior art date
Application number
BR112017022321-0A
Other languages
English (en)
Other versions
BR112017022321B1 (pt
Inventor
Vasseur-Demarcy Bérangère
Attali Pierre
Original Assignee
Monopar Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc. filed Critical Monopar Therapeutics Inc.
Publication of BR112017022321A2 publication Critical patent/BR112017022321A2/pt
Publication of BR112017022321B1 publication Critical patent/BR112017022321B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/08—Dichloro-benzenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção diz respeito à clonidina e/ou aos derivados de clonidina específicos, para uso na prevenção e/ou no tratamento de efeitos colaterais adversos da quimioterapia de agentes alquilantes, diferentes daqueles que resultam da inflamação mucosa. ela também diz respeito ao uso desta clonidina e/ou derivado de clonidina para a fabricação de uma composição farmacêutica pretendida para prevenir e/ou aliviar os efeitos colaterais adversos da quimioterapia de agentes alquilantes, diferentes daqueles que resultam da inflamação mucosa. esta invenção está adicionalmente dirigida para um kit compreendendo: (a) uma clonidina e/ou um derivado de clonidina, e (b) pelo menos um agente alquilante quimioterápico, como uma preparação combinada para o uso simultâneo, separado ou sequencial no tratamento de câncer.
BR112017022321-0A 2015-04-17 2015-04-17 Uso de clonidina e/ou de um derivado de clonidina para o tratamento de astenia e/ou fadiga devido a quimioterapia de agente alquilante BR112017022321B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/058419 WO2016165775A1 (en) 2015-04-17 2015-04-17 Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy

Publications (2)

Publication Number Publication Date
BR112017022321A2 true BR112017022321A2 (pt) 2018-07-03
BR112017022321B1 BR112017022321B1 (pt) 2023-03-14

Family

ID=52824258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022321-0A BR112017022321B1 (pt) 2015-04-17 2015-04-17 Uso de clonidina e/ou de um derivado de clonidina para o tratamento de astenia e/ou fadiga devido a quimioterapia de agente alquilante

Country Status (13)

Country Link
US (1) US10675271B2 (pt)
EP (1) EP3283072A1 (pt)
JP (1) JP6629344B2 (pt)
KR (1) KR102375047B1 (pt)
CN (1) CN108307631B (pt)
AU (1) AU2015391685B2 (pt)
BR (1) BR112017022321B1 (pt)
CA (1) CA2982460C (pt)
IL (1) IL255001B (pt)
MX (1) MX2017013396A (pt)
NZ (1) NZ736241A (pt)
WO (1) WO2016165775A1 (pt)
ZA (1) ZA201706884B (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5417070A (en) 1977-07-07 1979-02-08 Sony Tektronix Corp Waveform monitor
DE3168754D1 (en) * 1980-07-09 1985-03-21 Beecham Group Plc Clonidine derivatives useful in the treatment of diarrhoea
FR2665357B1 (fr) 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
US6610720B2 (en) * 2000-08-24 2003-08-26 Merck Frosst Canada & Co. Method for treating or preventing emesis
CN1329887A (zh) * 2001-06-29 2002-01-09 徐州颐华医药科技有限公司 可乐定作为镇痛剂的应用
US20060194878A1 (en) * 2002-10-07 2006-08-31 Lopaschuk Gary D Methods of cardioprotection using dichloroacetate in combination with an inotrope
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06002716A (es) 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
FR2889417B1 (fr) 2005-08-05 2008-02-08 Roquette Freres Proteines de pois texturee
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
EP1972332A1 (en) 2007-03-23 2008-09-24 BioAlliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
EP2368549A1 (en) 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
US10350695B2 (en) 2010-06-14 2019-07-16 Esab Ab Method of automatically setting a welding parameter for MIG/MAG welding and a controller for performing the method
RU2578412C1 (ru) * 2014-12-02 2016-03-27 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция для лечения астении и/или синдрома хронической усталости

Also Published As

Publication number Publication date
CA2982460C (en) 2023-05-23
JP2018511641A (ja) 2018-04-26
US10675271B2 (en) 2020-06-09
MX2017013396A (es) 2018-06-13
EP3283072A1 (en) 2018-02-21
KR102375047B1 (ko) 2022-03-15
US20180098966A1 (en) 2018-04-12
CN108307631B (zh) 2021-11-23
AU2015391685A1 (en) 2017-11-02
CA2982460A1 (en) 2016-10-20
WO2016165775A1 (en) 2016-10-20
CN108307631A (zh) 2018-07-20
KR20170137190A (ko) 2017-12-12
BR112017022321B1 (pt) 2023-03-14
IL255001A0 (en) 2017-12-31
IL255001B (en) 2020-10-29
JP6629344B2 (ja) 2020-01-15
AU2015391685B2 (en) 2021-07-01
ZA201706884B (en) 2021-02-24
NZ736241A (en) 2022-11-25

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
BR112018008918A2 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
CL2019000266A1 (es) Composición de cannabis.
DOP2020000023A (es) Nuevos derivados de quinolina
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
UY37789A (es) Nuevos derivados de azaquinolina
BR112017026294A2 (pt) formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
BR112018006368A2 (pt) composição para desempenho melhorado
BR112019006463A2 (pt) composição oral de canabinoides extraídos e métodos de uso da mesma
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2015, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2771 DE 15-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.